You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
衞信康(603676.SH):混合糖電解質注射液的藥品註冊申請 變更為“制證完畢-待發批件”
格隆匯 03-18 15:55

格隆匯 3 月 18日丨衞信康(603676.SH)公佈,公司近日國家藥品監督管理局(“國家藥監局”)網站獲悉,公司全資子公司內蒙古白醫製藥股份有限公司(“白醫製藥)提交的混合糖電解質注射液(受理號:CYHS1301907)藥品註冊申請在國家藥監局網站的辦理狀態變更為“制證-待發批件藥品批准文號:國藥準字H20213182

制證完畢-待發批件”狀態表示國家藥監局行政事項受理服務和投訴舉報中心批件製作結束待送達白醫製藥尚未取得正式藥品批件。

待白醫製藥取得國家藥監局簽發的正式文件後,根據上海證券交易所《上市公司行業信息披露指引第七號——醫藥製造的有關規定公司將及時履行信息披露義務,敬請廣大投資者謹慎決策,投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account